Ratings Recce Pharmaceuticals Ltd

Equities

RCE

AU000000RCE5

Delayed Australian S.E. Other stock markets 08:11:09 2024-05-02 pm EDT			5-day change	1st Jan Change
0.64 ^AUD	0.00%		-1.54%	+19.63%

Apr. 30	Recce Pharmaceuticals Ltd. Announces Safety Committee Approves High Dose of 4,000mg in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis	CI
Apr. 17	Recce Pharmaceuticals Ltd. Completes 5,000 RECCE 327 Doses Week Under Good Manufacturing Practice	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For the past twelve months, EPS forecast has been revised upwards.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
One of the major weak points of the company is its financial situation.
Based on current prices, the company has particularly high valuation levels.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
RECCE PHARMACEUTICALS LTD	+19.63%	87.43M	-
ELI LILLY AND COMPANY	+29.68%	699B	C+
NOVO NORDISK A/S	+25.07%	571B	B
JOHNSON & JOHNSON	-4.35%	364B	C+
MERCK & CO., INC.	+17.65%	326B	B-
ABBVIE INC.	+3.77%	286B	C+
ASTRAZENECA PLC	+14.68%	236B	B+
NOVARTIS AG	+4.71%	198B	B-
ROCHE HOLDING AG	-12.43%	194B	A+
PFIZER, INC.	-3.79%	154B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes